Zentiva Enters Biologics Market with EU Biosimilar Launch

Zentiva, a European manufacturer of affordable medicines, has launched its first biosimilar monoclonal antibody across the EU. This follows approval from the European Medicines Agency, marking Zentiva's strategic move into the biologics sector.

The company aims to enhance patient access to biologic medicines throughout Europe. Steffen Saltofte, CEO of Zentiva, stated that this entry into biosimilars aligns with their mission to provide high-quality, affordable treatments, facilitating sustainable growth in the dynamic pharmaceutical industry.

The biosimilar, used for bone condition treatment, is part of Zentiva's broader strategy to diversify beyond generics. By broadening its product portfolio, Zentiva seeks to meet growing healthcare needs and ensure the sustainability of healthcare systems.